Clinical Trial Update: An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab to investigator's choice chemotherapy as first-line therapy in stage IV or recurrent PD-L1+ non-small cell lung cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-07-26